Intellia Therapeutics
Search results
At Editas Medicine, we are pioneering the possible. Our mission and commitment is to harness the power and potential of CRISPR gene editing to develop a robust pipeline of medicines for people living with serious diseases around the world.
She joined Editas Medicine in July 2023 and is responsible for leading the drug discovery team and activities related to Editas Medicine’s pipeline of experimental medicines across all therapeutic areas and indications.
We are researching and developing two types of gene editing medicines: in vivo gene editing medicines that edit genes inside the body, and ex vivo gene editing medicines where the gene editing occurs outside the body to create edited cell medicines that are administered to patients.
Editas Medicine is a leading gene editing company dedicated to developing a robust pipeline of medicines to treat people living with serious diseases around the world. We have built a platform that utilizes CRISPR gene editing, a revolutionary approach to developing medicines.
May 4, 2022 · Editas Medicine is developing EDIT-202, a highly differentiated, iPSC-derived natural killer cell (iNK) investigational medicine with double knock-in and double knock-out edits. This approach has the potential to create an allogeneic “off-the-shelf” NK cell therapy medicine with enhanced activity against solid tumors.
May 10, 2024 · Access the latest press releases and other information from Editas Medicine, a leading gene editing company dedicated to developing CRISPR medicines for people living with serious diseases around the world.
Sep 29, 2021 · A positive safety profile has been observed through up to 15 months, with mostly mild adverse events primarily related to the procedure of retinal injection. The safety profile has allowed us to start enrolling and treating subjects in both the high-dose adult cohort and the mid-dose pediatric cohort.
Editas Medicine is building a leading gene editing company that uses CRISPR to develop medicines for people living with serious diseases. Learn more about Editas Medicine, our Inspiritas Culture, and how to join our team.
Oct 18, 2023 · Editas Medicine is focused on translating the power and potential of the CRISPR/Cas12a and CRISPR/Cas9 genome editing systems into a robust pipeline of medicines for people living with serious diseases around the world.
Nov 17, 2022 · CAMBRIDGE, Mass., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced clinical data from the Phase 1/2 BRILLIANCE trial of EDIT-101, an in vivo CRISPR/Cas9 genome editing medicine in a Company-sponsored webinar.
